Biosimilars accessible in the market for the treatment of cancer
- 1 August 2021
- journal article
- review article
- Published by Elsevier in Journal of Controlled Release
- Vol. 336, 112-129
Abstract
No abstract availableKeywords
Funding Information
- ICMR
This publication has 84 references indexed in Scilit:
- Pharmacovigilance and biosimilars: considerations, needs and challengesExpert Opinion on Biological Therapy, 2013
- The Continuum of Comparability Extends to Biosimilarity: How Much Is Enough and What Clinical Data Are Necessary?Clinical Pharmacology & Therapeutics, 2013
- Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropeniaJournal of Oncology Pharmacy Practice, 2011
- Efficient intracellular delivery of a pro-apoptotic peptide with a pH-responsive carrierReactive and Functional Polymers, 2011
- Biosimilar agents in oncology/haematology: from approval to practiceEuropean Journal of Haematology, 2010
- Understanding Equivalence and Noninferiority TestingJournal of General Internal Medicine, 2010
- Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysisCanadian Medical Association Journal, 2009
- Toward biosimilar monoclonal antibodiesNature Biotechnology, 2008
- Immunogenicity of therapeutic proteins. Part 3: Impact of manufacturing changesBiotechnology Advances, 2007
- Antibody humanization: a case of the ‘Emperor’s new clothes’?Immunology Today, 2000